These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 27498345)

  • 1. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
    McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
    J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa.
    Terracina M; Posteraro P; Schubert M; Sonego G; Atzori F; Zambruno G; Bruckner-Tuderman L; Castiglia D
    J Invest Dermatol; 1998 Nov; 111(5):744-50. PubMed ID: 9804332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.
    Goto M; Sawamura D; Nishie W; Sakai K; McMillan JR; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Dec; 126(12):2614-20. PubMed ID: 16778792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.
    Bornert O; Kühl T; Bremer J; van den Akker PC; Pasmooij AM; Nyström A
    Mol Ther; 2016 Aug; 24(7):1302-11. PubMed ID: 27157667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
    Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splice modulation strategy applied to deep intronic variants in
    Pironon N; Bourrat E; Prost C; Chen M; Woodley DT; Titeux M; Hovnanian A
    Proc Natl Acad Sci U S A; 2024 Aug; 121(35):e2401781121. PubMed ID: 39159368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense-mediated exon skipping to reframe transcripts.
    Turczynski S; Titeux M; Pironon N; Hovnanian A
    Methods Mol Biol; 2012; 867():221-38. PubMed ID: 22454065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin.
    Bremer J; van den Akker PC
    Methods Mol Biol; 2022; 2434():185-190. PubMed ID: 35213017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
    Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
    Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
    Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
    Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
    van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
    J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Dunnill MG; McGrath JA; Richards AJ; Christiano AM; Uitto J; Pope FM; Eady RA
    J Invest Dermatol; 1996 Aug; 107(2):171-7. PubMed ID: 8757758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.
    Woodley DT; Hao M; Kwong A; Levian B; Cogan J; Hou Y; Mosallaei D; Kleinman E; Zheng K; Chung C; Kim G; Peng D; Chen M
    Br J Dermatol; 2024 Jul; 191(2):267-274. PubMed ID: 38366625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosa.
    Koga H; Hamada T; Ishii N; Fukuda S; Sakaguchi S; Nakano H; Tamai K; Sawamura D; Hashimoto T
    J Dermatol; 2011 May; 38(5):489-92. PubMed ID: 21352278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation.
    Hovnanian A; Rochat A; Bodemer C; Petit E; Rivers CA; Prost C; Fraitag S; Christiano AM; Uitto J; Lathrop M; Barrandon Y; de Prost Y
    Am J Hum Genet; 1997 Sep; 61(3):599-610. PubMed ID: 9326325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.